[Translation] A Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of XZ126 in patients with solid tumors who have failed prior treatment.
主要研究目的:
评价XZ126在既往治疗失败的实体瘤患者中的安全性和耐受性;
评估XZ126在既往治疗失败的实体瘤患者中的剂量限制性毒性(DLT),确定最大耐受剂量(MTD)和/或Ⅱ期推荐剂量(RP2D)。
次要研究目的:
评价XZ126在既往治疗失败的实体瘤患者中的药代动力学(PK)特征;
评价XZ126在既往治疗失败的实体瘤患者中的初步有效性;
评价XZ126与原研Jevtana®(卡巴他赛注射液)在既往治疗失败的实体瘤患者中的PK、耐受性及疗效等方面的差异。
[Translation] Primary Study Objectives:
To evaluate the safety and tolerability of XZ126 in patients with previously untreated solid tumors;
To assess the dose-limiting toxicities (DLT) of XZ126 in patients with previously untreated solid tumors, and to determine the maximum tolerated dose (MTD) and/or the recommended dose for Phase II (RP2D).
Secondary Study Objectives:
To evaluate the pharmacokinetic (PK) characteristics of XZ126 in patients with previously untreated solid tumors;
To evaluate the preliminary efficacy of XZ126 in patients with previously untreated solid tumors;
To evaluate the differences in PK, tolerability, and efficacy between XZ126 and the original Jevtana® (cabatataxel injection) in patients with previously untreated solid tumors.